about
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationAgents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondEndpoints in stem cell trials in ischemic heart failureRecommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of AcademicAgents with vasodilator properties in acute heart failure: how to design successful trialsMode of Death After Acute Heart Failure Hospitalization - A Clue to Possible MechanismsEffect of nesiritide in patients with acute decompensated heart failureTorsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairmentPermutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHFEndothelial damage due to air pollutionDopaminergic Drugs in Congestive Heart FailureHeart failure 2016: still more questions than answers.Cardiorenal Interactions.School and family-based interventions for promoting a healthy lifestyle among children and adolescents in Italy: a systematic review.Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure.Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome.Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry.Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis.Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).[Prognostic significance of clinical, ergometric and coronarographic data in patients soon after myocardial infarction]Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials).Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.Relaxin: review of biology and potential role in treating heart failure.Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.Heart failure in elderly patients: distinctive features and unresolved issues.Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance.ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of CardioloThe role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T.Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.The role of the kidney in heart failure.Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
P50
Q22306351-9846CF6D-791D-409B-918F-53A07D278DC6Q24645066-BB4AAA2F-0A23-48F4-B950-4EC889A3794BQ26796330-966AAC25-748E-4439-85A5-B94F7E4C0A7CQ27008175-D61B7457-EC1F-4227-97F3-2192EC60867EQ28084239-D312988C-F5D7-4DC2-BAF1-0DE8AC2E4A2AQ28084842-7DCE9DB4-719E-4469-B757-75B93F27BA74Q28242547-6E312203-BEB6-4F11-88F5-844240FB41C0Q28271500-A4D4B211-6248-42DE-B320-408FFEBD963BQ28297684-C3D9CCB3-23C4-4A39-A1A3-AFA684E4D778Q28740781-31F3C2F5-A0D2-4CC4-8D45-554A72F16043Q28744360-65A0DAE1-08FD-46AC-8EEB-BDC723B9C851Q29392189-A2B6EF25-FF16-44A0-84BB-B19547C494A5Q30241376-2F5FCDCB-C50E-4009-9537-090B0910D6DBQ30249193-FB3AC93E-F4F9-4E20-9F8B-63E1257EB815Q30250344-12509AAA-68B2-4915-A362-E26ED1CB5002Q30585648-10789303-0D1E-4EAD-8F59-94B9D24DD597Q30655054-6F4D075D-DA03-4151-B65F-5692A9E9BAABQ30724401-9227C487-8398-4D54-ABCA-378BBE14D895Q30837842-6CCFAC4D-DF69-4671-88A9-5E53BC642D1FQ30994514-AB789606-C85D-4C14-BDD3-86C25796DF50Q31094492-49AF6D4C-E6CA-423E-AFF5-FECB3E9D62ACQ31126055-33E37F23-6D61-44E0-AD42-8080668A5F40Q31141404-BE30D1B0-F9F3-4895-B179-089724BB0F9DQ33845755-3F166526-3B9D-4C30-B1D6-2A8E23CB5D4DQ33873275-D32AD581-E8C3-4563-B46D-5C9A06BE78ADQ33996248-494031BD-18B3-4661-8780-6C0C7275BF39Q34148325-B0BC2700-238C-41CA-8A56-6594D3DC1006Q34164006-6C443642-32DA-4DD5-B8D2-1F81531B532EQ34213067-F08B01A9-661A-49C4-9A48-B37DA64020C5Q34248538-0436ABA4-6264-4527-97F4-A15854134203Q34310960-AFCC32C3-BC39-4EBC-BB13-48D9892F6088Q34337289-D6A7ED17-CD00-4C27-BADD-6EFA8B21D735Q34375466-ACBEF41E-9B15-4D20-B722-330403CD6D5BQ34389554-D641A25F-0832-4611-A01D-95F00FE1D090Q34471934-DF115E33-D621-41E7-8911-CECEDDA1ADD8Q34560910-7584078A-88C8-4192-A2DB-03806167A28CQ34580385-E6370537-418D-4113-9570-C6C9296F8EEBQ34622692-4943FDFA-5374-4576-9A88-33117523B5D6Q34641418-3D05BCBD-74FD-4A64-B0DE-FFAD1A657FD8Q34646866-88D059B8-DED2-4A3A-826D-EAF44F920D72
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Metra
@ast
Marco Metra
@en
Marco Metra
@es
Marco Metra
@nl
Marco Metra
@sl
type
label
Marco Metra
@ast
Marco Metra
@en
Marco Metra
@es
Marco Metra
@nl
Marco Metra
@sl
prefLabel
Marco Metra
@ast
Marco Metra
@en
Marco Metra
@es
Marco Metra
@nl
Marco Metra
@sl
P106
P1153
7006770735
P21
P31
P496
0000-0001-6691-8568